|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/15/20 Onconova Therapeutics, Inc. 10-Q 3/31/20 64:5M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 328K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
30: R1 Document and Entity Information HTML 48K
59: R2 Condensed Consolidated Balance Sheets HTML 90K
42: R3 Condensed Consolidated Balance Sheets HTML 38K
(Parenthetical)
21: R4 Condensed Consolidated Statements of Operations HTML 48K
31: R5 Condensed Consolidated Statements of Comprehensive HTML 35K
Loss
60: R6 Consolidated Statement of Stockholders' Equity HTML 56K
(Deficit)
43: R7 Condensed Consolidated Statements of Cash Flows HTML 69K
22: R8 Nature of Business HTML 41K
29: R9 Summary of Significant Accounting Policies HTML 55K
52: R10 Revenue HTML 50K
58: R11 Net Loss Per Share of Common Stock HTML 33K
36: R12 Warrants HTML 184K
14: R13 Balance Sheet Detail HTML 82K
51: R14 Fair Value Measurements HTML 88K
57: R15 Stock-Based Compensation HTML 154K
35: R16 Research Agreements HTML 22K
13: R17 License and Collaboration Agreements HTML 32K
53: R18 Related-Party Transactions HTML 24K
56: R19 Securities Registrations and Sales Agreements HTML 25K
34: R20 Summary of Significant Accounting Policies HTML 65K
(Policies)
24: R21 Revenue (Tables) HTML 51K
48: R22 Net Loss Per Share of Common Stock (Tables) HTML 33K
64: R23 Warrants (Tables) HTML 185K
33: R24 Balance Sheet Detail (Tables) HTML 85K
23: R25 Fair Value Measurements (Tables) HTML 82K
47: R26 Stock-Based Compensation (Tables) HTML 149K
63: R27 Nature of Business - Liquidity (Details) HTML 79K
32: R28 Summary of Significant Accounting Policies - HTML 21K
Segment Information (Details)
25: R29 Summary of Significant Accounting Policies - HTML 29K
Leases (Details)
16: R30 Revenue (Details) HTML 38K
37: R31 Net Loss Per Share of Common Stock (Details) HTML 27K
54: R32 Warrants (Details) HTML 131K
49: R33 Balance Sheet Detail - Prepaid Expenses and Other HTML 33K
Current Assets (Details)
17: R34 Balance Sheet Detail Property and Equipment HTML 28K
(Details)
38: R35 Balance Sheet Detail - Accrued Expenses and Other HTML 29K
Current Liabilities (Details)
55: R36 Fair Value Measurements (Details) HTML 34K
50: R37 Fair Value Measurements - Rights Offering HTML 42K
(Details)
15: R38 Fair Value Measurements - Weighted-average HTML 30K
assumptions (Details)
39: R39 Fair Value Measurements - Fair Value Hierarchy HTML 30K
Table (Details)
19: R40 Fair Value Measurements - Transfers (Details) HTML 28K
26: R41 Stock-Based Compensation (Details) HTML 41K
61: R42 Stock-Based Compensation - Expense (Details) HTML 29K
44: R43 Stock-Based Compensation - Activity (Details) HTML 78K
20: R44 Stock-Based Compensation - Outstanding and HTML 62K
Exercisable (Details)
27: R45 Stock-Based Compensation - Unrecognized HTML 25K
Compensation Expense (Details)
62: R46 Stock-Based Compensation - Fair Value Assumptions HTML 37K
(Details)
45: R47 Research Agreements (Details) HTML 23K
18: R48 License and Collaboration Agreements (Details) HTML 68K
28: R49 Related-Party Transactions (Details) HTML 30K
41: R50 Securities Registrations and Sales Agreements - HTML 49K
Underwriting agreement with HCW (Details)
40: XML IDEA XML File -- Filing Summary XML 111K
12: EXCEL IDEA Workbook of Financial Reports XLSX 65K
6: EX-101.INS XBRL Instance -- ontx-20200331 XML 1.58M
8: EX-101.CAL XBRL Calculations -- ontx-20200331_cal XML 98K
9: EX-101.DEF XBRL Definitions -- ontx-20200331_def XML 385K
10: EX-101.LAB XBRL Labels -- ontx-20200331_lab XML 953K
11: EX-101.PRE XBRL Presentations -- ontx-20200331_pre XML 672K
7: EX-101.SCH XBRL Schema -- ontx-20200331 XSD 137K
46: ZIP XBRL Zipped Folder -- 0001104659-20-062608-xbrl Zip 113K
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Onconova Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Fruchtman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: May 15, 2020 | /s/ Steven M. Fruchtman, M.D. |
| Steven M. Fruchtman, M.D. | |
|
President and Chief Executive Officer ( Principal Executive and Principal Operating Officer ) |
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/15/20 | CORRESP, S-3/A | ||
| For Period end: | 3/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/11/21 Onconova Therapeutics, Inc. 424B5 1:429K Toppan Merrill/FA 2/10/21 Onconova Therapeutics, Inc. 424B5 1:431K Toppan Merrill/FA 1/08/21 Onconova Therapeutics, Inc. 424B5 1:292K Toppan Merrill/FA |